Literature DB >> 19544433

Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.

John J P Kelly1, Owen Stechishin, Andrew Chojnacki, Xueqing Lun, Beichen Sun, Donna L Senger, Peter Forsyth, Roland N Auer, Jeff F Dunn, J Gregory Cairncross, Ian F Parney, Samuel Weiss.   

Abstract

Primary glial tumors of the central nervous system, most commonly glioblastoma multiforme (GBM), are aggressive lesions with a dismal prognosis. Despite identification and isolation of human brain tumor stem cells (BTSCs), characteristics that distinguish BTSCs from neural stem cells remain to be elucidated. We cultured cells isolated from gliomas, using the neurosphere culture system, to understand their growth requirements. Both CD133(+) and CD133(-) adult GBM BTSCs proliferated in the absence of exogenous mitogenic stimulation and gave rise to multipotent GBM spheres that were capable of self-renewal. Epidermal growth factor (EGF) and fibroblast growth factor-2 enhanced GBM BTSC survival, proliferation, and subsequent sphere size. Blockade of EGF receptor (EGFR) signaling reduced exogenous mitogen-independent GBM sphere growth. Implantation of as few as 10 exogenous mitogen-independent GBM BTSCs led to the formation of highly invasive intracranial tumors, which closely resembled human GBMs, in immunocompromised mice. These results demonstrate that exogenous mitogen independence, mediated in part through EGFR signaling, is one characteristic that distinguishes CD133(+) and CD133(-) GBM BTSCs from neural stem cells. This novel experimental system will permit the elucidation of additional constitutively activated mechanisms that promote GBM BTSC survival, self-renewal, and proliferation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19544433     DOI: 10.1002/stem.98

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  99 in total

1.  An in vivo patient-derived model of endogenous IDH1-mutant glioma.

Authors:  H Artee Luchman; Owen D Stechishin; N Ha Dang; Michael D Blough; Charles Chesnelong; John J Kelly; Stephanie A Nguyen; Jennifer A Chan; Aalim M Weljie; J Gregory Cairncross; Samuel Weiss
Journal:  Neuro Oncol       Date:  2011-12-13       Impact factor: 12.300

2.  Evidence for label-retaining tumour-initiating cells in human glioblastoma.

Authors:  Loic P Deleyrolle; Angus Harding; Kathleen Cato; Florian A Siebzehnrubl; Maryam Rahman; Hassan Azari; Sarah Olson; Brian Gabrielli; Geoffrey Osborne; Angelo Vescovi; Brent A Reynolds
Journal:  Brain       Date:  2011-04-22       Impact factor: 13.501

Review 3.  The cancer stem cell paradigm: a new understanding of tumor development and treatment.

Authors:  Johnathan D Ebben; Daniel M Treisman; Michael Zorniak; Raman G Kutty; Paul A Clark; John S Kuo
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

Review 4.  Glioblastoma cancer stem cells: Biomarker and therapeutic advances.

Authors:  Kelli B Pointer; Paul A Clark; Michael Zorniak; Bahauddeen M Alrfaei; John S Kuo
Journal:  Neurochem Int       Date:  2014-03-19       Impact factor: 3.921

5.  ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor-initiating cells.

Authors:  Susobhan Sarkar; Franz J Zemp; Donna Senger; Stephen M Robbins; V Wee Yong
Journal:  Neuro Oncol       Date:  2015-02-01       Impact factor: 12.300

6.  Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres.

Authors:  Eli E Bar; Alex Lin; Vasiliki Mahairaki; William Matsui; Charles G Eberhart
Journal:  Am J Pathol       Date:  2010-07-29       Impact factor: 4.307

7.  PDGF-B Can sustain self-renewal and tumorigenicity of experimental glioma-derived cancer-initiating cells by preventing oligodendrocyte differentiation.

Authors:  Yiwen Jiang; Maria Boije; Bengt Westermark; Lene Uhrbom
Journal:  Neoplasia       Date:  2011-06       Impact factor: 5.715

8.  In vitro modeling of glioblastoma initiation using PDGF-AA and p53-null neural progenitors.

Authors:  Alexandra K Bohm; Jessica DePetro; Carmen E Binding; Amanda Gerber; Nicholas Chahley; N Dan Berger; Mathaeus Ware; Kaitlin Thomas; U Senapathi; Shazreh Bukhari; Cindy Chen; Erin Chahley; Cameron Grisdale; Sam Lawn; Yaping Yu; Raymond Wong; Yaoqing Shen; Hiba Omairi; Reza Mirzaei; Nourah Alshatti; Haley Pedersen; Wee Yong; Samuel Weiss; Jennifer Chan; P J Cimino; John Kelly; Steve Jones; Eric Holland; Michael Blough; Gregory Cairncross
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

9.  MRI monitoring of monocytes to detect immune stimulating treatment response in brain tumor.

Authors:  Runze Yang; Susobhan Sarkar; Daniel J Korchinski; Ying Wu; V Wee Yong; Jeff F Dunn
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

10.  Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Authors:  Franz J Zemp; Xueqing Lun; Brienne A McKenzie; Hongyuan Zhou; Lori Maxwell; Beichen Sun; John J P Kelly; Owen Stechishin; Artee Luchman; Samuel Weiss; J Gregory Cairncross; Mark G Hamilton; Brian A Rabinovich; Masmudur M Rahman; Mohamed R Mohamed; Sherin Smallwood; Donna L Senger; John Bell; Grant McFadden; Peter A Forsyth
Journal:  Neuro Oncol       Date:  2013-04-12       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.